Dynavax Technologies (NASDAQ:DVAX) Sees Large Volume Increase – Here’s What Happened

Dynavax Technologies Corporation (NASDAQ:DVAX) shares saw unusually-high trading volume on Monday . Approximately 4,646,685 shares changed hands during mid-day trading, an increase of 122% from the previous session’s volume of 2,096,736 shares.The stock last traded at $15.3750 and had previously closed at $15.38.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on DVAX. William Blair downgraded shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a report on Wednesday, December 24th. Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $24.33.

Dynavax Technologies Stock Down 0.0%

The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -41.55 and a beta of 0.88. The firm’s 50-day simple moving average is $11.10 and its two-hundred day simple moving average is $10.58.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, topping the consensus estimate of $0.14 by $0.07. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%.The business had revenue of $94.88 million for the quarter, compared to analyst estimates of $94.00 million. Sell-side analysts predict that Dynavax Technologies Corporation will post 0.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Dynavax Technologies

Several hedge funds have recently added to or reduced their stakes in DVAX. Hantz Financial Services Inc. lifted its stake in Dynavax Technologies by 236.9% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 2,710 shares in the last quarter. LSV Asset Management acquired a new position in shares of Dynavax Technologies in the third quarter worth $89,000. Osaic Holdings Inc. lifted its position in shares of Dynavax Technologies by 15.1% in the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 1,226 shares in the last quarter. Callan Family Office LLC acquired a new stake in shares of Dynavax Technologies during the second quarter valued at $107,000. Finally, CIBC Bancorp USA Inc. purchased a new stake in Dynavax Technologies during the 3rd quarter worth about $109,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.